About: SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation
Creator	Bauer, G Cinatl, J Rabenau, H Biesert, L Doerr, H Pharmazeutika, Octapharma Schmidt, T
Source	Elsevier; Medline; PMC
abstract	Abstract SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. SARS-CoV viraemia does not seem to reach high titres, however, it has to be excluded that virus transmission may occur via blood transfusion or application of therapeutic plasma products, e.g. fresh-frozen plasma or single components derived thereof. Manufacturing processes of all plasma derivatives are required to comprise dedicated virus inactivation/removal steps. Treatment with a mixture of solvent and detergent (SD) has successfully been applied to inactivate the most members of the transfusion-relevant viruses without affecting therapeutic properties of the products. The SD treatment irreversibly disrupts the lipid envelope of viruses such as HIV, HBV, HCV, HGV and CMV. In this study we evaluated the manufacturing process of an immunoglobulin preparation (OCTAGAM, manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria) for its capacity to inactivate the SARS-CoV. Our results demonstrate that SARS-CoV was completely inactivated below the limit of detection. This was found to occur within 1min of SD treatment.
has issue date	2005-06-30(xsd:dateTime)
bibo:doi	10.1016/j.biologicals.2005.01.003
bibo:pmid	15939287
has license	els-covid
sha1sum (hex)	442316a2541be888ac2a69d732acb7b41958925a
schema:url	https://doi.org/10.1016/j.biologicals.2005.01.003
resource representing a document's title	SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation
has PubMed Central identifier	PMC7128630
has PubMed identifier	15939287
schema:publication	Biologicals
resource representing a document's body	covid:442316a2541be888ac2a69d732acb7b41958925a#body_text
is schema:about of	named entity 'SOLVENT' named entity 'TREATED' named entity 'study' named entity 'September' named entity 'SARS-CoV' named entity 'solvent' named entity 'PERSON-TO-PERSON TRANSMISSION ' named entity 'SAFETY' named entity 'CORONAVIRUS' named entity 'HBV' named entity 'IMMUNOGLOBULIN PREPARATION' named entity 'HIGH' named entity 'VIRUS' named entity 'INFECTIONS' named entity 'MIXTURE' named entity 'NEARLY' named entity 'PLASMA PRODUCTS' named entity 'CASES' named entity '800' covid:arg/442316a2541be888ac2a69d732acb7b41958925a named entity 'VIRAEMIA' named entity 'RELEVANT' named entity '8000' named entity 'TREATMENT' named entity 'IS A' named entity 'OCCUR' named entity 'CMV' named entity 'DIRECT' named entity 'DOES NOT' named entity 'SINGLE' named entity 'MEMBERS' named entity 'MANUFACTURING PROCESSES' named entity 'OUR' named entity 'SARS' named entity '28S' named entity 'TRANSFUSION' named entity 'CORONAVIRUS' named entity 'COMPONENTS' named entity 'HGV' named entity 'STEPS' named entity 'AFFECTING' named entity 'HAVE' named entity 'COMPLETELY' named entity 'VIRUSES' named entity 'COMPRISE' named entity 'LIPID' named entity 'DEDICATED' named entity 'RESULTS' named entity 'STUDY' named entity 'CAPACITY' named entity 'PLASMA' named entity 'SEPTEMBER' named entity 'VIRUS INACTIVATION' named entity 'MIN' named entity 'EVALUATED' named entity 'MANUFACTURING PROCESS' named entity 'DETERGENT' named entity 'BLOOD TRANSFUSION' named entity 'EXCLUDED' named entity 'RULED OUT' named entity 'RESPIRATORY' named entity 'DEATHS' named entity 'HIV' named entity 'ITS' named entity 'HUMAN' named entity 'OCTAPHARMA' named entity 'HCV' named entity 'ENVELOPE' named entity 'IMMUNOGLOBULIN PREPARATION' named entity 'DERIVED' named entity 'PATHOGENIC' named entity 'INACTIVATED' named entity 'H.%' named entity 'LIMIT OF DETECTION' named entity 'SOLVENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software